Analysed MINK THERAPEUTICS INC (INKT:NASDAQ) News Sources
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
17-04-2026
yahoo.com
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
03-04-2026
yahoo.com
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
03-04-2026
yahoo.com
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
02-04-2026
yahoo.com
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
01-04-2026
yahoo.com
MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ...
31-03-2026
yahoo.com
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
31-03-2026
yahoo.com
What is the current price of MINK THERAPEUTICS INC (INKT:NASDAQ)?
The current price of MINK THERAPEUTICS INC (INKT:NASDAQ) is $11.74.
MINK THERAPEUTICS INC (INKT:NASDAQ) absolute price change since previous trading day?
The absolute price change of MINK THERAPEUTICS INC (INKT:NASDAQ) since the previous trading day is $-1.08.
MINK THERAPEUTICS INC (INKT:NASDAQ) percentage price change since previous trading day?
The percentage price change of MINK THERAPEUTICS INC (INKT:NASDAQ) since the previous trading day is -8.4243%.
What is the most recent average sentiment score for MINK THERAPEUTICS INC (INKT:NASDAQ)?
The most recent average sentiment score for MINK THERAPEUTICS INC (INKT:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for MINK THERAPEUTICS INC (INKT:NASDAQ)?
The most recent sentiment for MINK THERAPEUTICS INC (INKT:NASDAQ) is .
SEC-8K** Filing Available For MINK THERAPEUTICS INC (INKT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.